Menlo Park, Calif. and Dallas, Texas – August 3, 2021 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will host 1×1 meetings at two upcoming virtual investor conferences in August:
- Canaccord Genuity 41st Annual Growth Conference
Dates: August 10 – 12, 2021 - Wedbush PacGrow Healthcare Conference
Dates: August 10 – 11, 2021
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
Media Contact:
Will Zasadny
Canale Communications, Inc.
[email protected]
(619) 961-8848
Investor Contact:
Sarah McCabe
Stern Investor Relations
[email protected]
[email protected]
